-
MSD, Ferring Pharmaceuticals and the World Health Organization – Working Together to Prevent Excessive Bleeding in Women after Childbirth
inFerring Pharmaceuticals and MSD, known as Merck in the United States and Canada, today announced their collaboration with the World Health…
0 -
New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists
inA paper published today in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin…
-
Launch of CORTIMENT® (budesonide)
TIMELINES oninLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
-
Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific
inFerring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013…
-
MISODEL™, Ferring’s removable misoprostol vaginal delivery system, approved for labour induction in European Decentralised Procedure
inFerring Pharmaceuticals announced today that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction…
-
Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan
inFerring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and…
-
Ferring presents phase III data for a controlled release misoprostol vaginal delivery system for labour induction at the First European Congress on Intrapartum Care
inData from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated…
-
Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation
inFerring Pharmaceuticals today announced it has initiated enrolment of patients in two phase III clinical trials…
-
Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting
inThe following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego…
-
New data highlight considerable burden of Nocturia
inNew data presented today at the European Association of Urology (EAU) congress show that nocturia (waking up one or more times to void at night)…
Author archive for pulse
Articles by: pulse